Looking for leads, investment insights, or competitive intelligence?
News about Amgen
Scientists are ready to move an experimental treatment into phase 1 trials.
Coherus BioSciences shares took a massive hit on Monday.
Critics accused the Charging Bull's new Wall Street companion of being an advertisement in disguise.
But Dupixent's high cost could be a problem.
Hospitals win, health insurers not so much.